Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has issued an update.
CARsgen Therapeutics has extended the term of its existing share repurchase plan to run until the conclusion of its next annual general meeting, after having already bought back 7,627,000 shares under its 2025 repurchase mandate. Funded by non-IPO sources such as business development and interest income, the move is framed by the board as a signal that the company’s share price undervalues its long-term growth prospects and as a measure to enhance shareholder value. Separately, substantial shareholder YIJIE Biotech Holding Limited and its concert parties have increased their stake to about 38.2% of issued shares (excluding treasury shares), a development the board interprets as further market confidence in CARsgen’s long-term investment appeal, albeit with the caveat that future buybacks remain discretionary and subject to market conditions.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited is a biotechnology company focused on developing innovative cell therapies, particularly CAR-T treatments, for cancer. Listed on the Hong Kong Stock Exchange, the group operates through subsidiaries and affiliated entities, targeting both domestic and global oncology markets with advanced immunotherapy products.
Average Trading Volume: 1,968,220
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.6B
Find detailed analytics on 2171 stock on TipRanks’ Stock Analysis page.